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Abstract
Preeclampsia is a multisystem progressive disorder characterized by new onset of 
hypertension and proteinuria or hypertension and significant end-organ dysfunc-
tion with or without proteinuria after 20 weeks of pregnancy. Recently, it has been 
shown that early preeclampsia is associated with abnormalities in oxygen sensing 
since early preeclampsia; the placenta is unable to regulate hypoxia-inducible factor 
1- (HIF1-) alpha levels. The risk factors that are involved in the development of pre-
eclampsia are also the symptoms of the metabolic syndrome and glucose metabolism 
disorders such as diabetes mellitus as well as insulin resistance, increased body mass 
index (>35 kg/m2), and elevated diastolic blood pressure > 80 mm Hg. Further risk 
factors are positive family history of preeclampsia, multiple pregnancy, pregnant 
women over 40 years, preexisting renal disease, and clotting disorders. All biophysi-
cal and biochemical markers are shown to be used for prediction of preeclampsia. 
Meanwhile, it has been obvious that a single examined marker might not have the 
conclusion to accurately predict subsequent preeclamptic risk. Consequently, it 
seems to be convincing to apply history, biophysical, and several biochemical param-
eters to conclude the best possible detection rate.
Keywords: preeclampsia, maternal risk factors, biophysical, several biochemical 
parameters
1. Introduction
Preeclampsia is a multisystem progressive disorder characterized by the new onset 
of hypertension and proteinuria or hypertension and significant end-organ dysfunc-
tion with or without proteinuria, in the last half of pregnancy or postpartum. The 
genesis of the disease is laid down in early pregnancy and is characterized anatomi-
cally by abnormal remodeling of the maternal spiral arteries at the placental site.
2–The prevalence of pregnant women affected by preeclampsia (PE) [1] is 7%, com-
monly occurs in the second half of pregnancy and is basically identified by the existing 
symptoms of hypertension and proteinuria. HELLP syndrome (hemolysis, elevated 
liver enzymes, and low platelet count) may develop among 5–8% of these women. 
Preeclampsia is one of the major triggers of maternal and fetal death worldwide and a 
common cause of premature labor. Women with preeclamptic history are at high risk 
for cardiovascular diseases later in life [2]. Lowering morbidity and mortality resulting 
from this disease of lifestyle changes, and its preventive actions should be the main 
objective. The preventive treatment for those with the preeclamptic high risk has the 
potential to be a predictive tool also for anticipating other health disorders with serious 
consequences for the mothers, their offsprings, and health-care systems themselves.
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2. Pathogenesis
The placenta applies a significant factor in the pathogenesis of preeclampsia 
because the symptoms of PE can happen in molar pregnancy, which lacks a fetus, 
and the disease disappears once the placenta is delivered.
Uteroplacental vascular insufficiency triggers fetus malnutrition and inadequate 
oxygen and nutrients. It is then identified clearly that the impact of such undernu-
trition condition seemingly causes coronary heart disease and hypertension in the 
future life [3–5]. It is easily noticed that the human placenta is only a temporary 
organ, but its effect on the fetus is protecting life. The correct function of the placenta 
necessitates the correct differentiation of the trophectoderm to set up a nutrition link 
between the embryo and mother [6]. In spite of numerous years of research, a holistic 
comprehension molecular pathogenesis of preeclampsia remains unidentified.
The present study of pathogenesis of preeclampsia carried out by Christopher 
Redman and Ian Sergent is assumed to happen in two-phase series of unsuitable 
placental condition in the first and at the beginning of the second trimester, and 
it badly influences the rest of the pregnancy period [7, 8]. Anatomically, placental 
diagnosis uncovers that the most affected part of this illness is basal plate in which 
the cytotrophoblast (CBT) exists [9]. In preeclamptic condition, both interstitial 
CTB and endovascular invasion are not deep, and consequently, it triggers impaired 
vascular remodeling of the spiral arteries [10]. The next phase of preeclampsia is 
assumed maternity-related reactions to abnormal placentation as a consequence of 
endothelial dysfunction and an imbalance in circulating angiogenic/vasculogenic 
factors such as soluble vascular endothelial growth factor receptor-1 (VEGFR-1, 
sFlt-1), placental growth factor (PlGF), and the changing complete growth of 
factor-beta receptor endoglin (CD105) [9, 11, 12] (Figure 1).
Figure 1. 
In normal pregnancies, sFlt-1 and PIGF are in physiological angiogenic balance. Various factors and mediators 
influence the trophoblast invasion and placentation and in case of preeclampsia cause excessive production and 
liberation of sFlt-1 levels result in an unphysiological increase of the sFlt-1/PIGF ratio (angiogenic imbalance). 
Measurement of sFlt-1/PIGF ratio helps to identify women with preeclampsia and those who are likely to 
develop preeclampsia. ATI AA, angiotensin-converting enzyme autoantibodies. NK cells, natural killer cells.
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2.1 New insights of molecule
There is substantial fact that a nonphysiological hypoxic environment subse-
quently in pregnancy could create such decontrol of angiogenic factors at the moth-
erly embryonic connection. Lately, it has been indicated that the early preeclampsia 
is linked to anomalies regarding O2 sensing since preliminary preeclamptic placen-
tas failed to control hypoxia-inducible factor 1- (HIF1-) alpha levels [13]. Incessant 
vulnerability in nonphysiological O2 levels in preeclampsia lowers vascular endothe-
lial growth factor (VEGF), whereas sFlt-1 is really responsive. It is clearly accepted 
that produced sFlt-1 tied to VEGF and PlGF with huge similarity and consequently 
lowers their ability to link to their receptors [14]. The transformations act like an 
antiangiogenic treatment indicated in medical tests influencing similar medical 
symptoms such as angiogenesis dysfunction especially in vessels maturity, hyper-
tension, proteinuria, and edema [14, 15]. Verlohren et al. [16] stated that the sFlt-1/
PlGF ratio is essential to recognize females at risk for delivery and is a convincing 
tool to differentiate between different types of pregnancy-related hypertensive 
illnesses. Females are classified preeclamptic, at gestational age <34 weeks; the 
circulating sFlt-1/PlGF ratio predicts adverse outcomes occurring within 2 weeks 
[17, 18]. However, the mechanisms by which placenta-derived sFlt-1 gains access to 
the maternal circulation remain unclear. Rajakumar et al. [19] report that the sFlt-1 
protein is highly enriched in syncytial knots which is easily detach from the syncy-
tiotrophoblast—a finding which is increased in preeclampsia. These multinucleated 
aggregates are metabolically active and are capable of de novo synthesis and may 
thus contribute to the maternal vascular injury in PE [19].
Moreover we revealed a deregulated expression of another molecule found in the 
bulk of changed molecules in PE: the matricellular CCN3 protein which lead to an 
imbalance in proliferation and migration of human trophoblast cells and could con-
tribute to the shallow invasion of trophoblast cells into the decidual compartment 
and spiral arteries observed in preeclampsia [20–23]. In addition, in our recent 
publication, we could show that the cholesterol transporter ABCA1 is deregulated 
in early-onset preeclampsia resulted from placental hypoxia [24, 25]. These results 
focused on the importance of the maternal-fetal cholesterol transport for adequate 
development of the fetus.
Microarray datasets of basal plate biopsies of both normal placentation and PE 
(24–36 weeks) demonstrated novel observations indicating increased expression 
of the leptin receptor Siglec-6 and pappalysin (PAPP-A2), a metalloproteinase 
that cleaves insulin-like growth factor (IGF)-binding protein-5 (IGFBP-5), in 
PE placentas compared to controls. Overall, these results suggest alterations in 
important biological processes including pathways that are regulated by leptin 
and IGF signals [9].
3. Early diagnosis
The aim for the early diagnosis is to start a preventive therapy by administration 
of 100 mg acetylsalicylic acid (ASS, aspirin) before 16 weeks of pregnancy (reduc-
tion of risk for severe preeclampsia: RR 0.1; 95% KI 0.1–0.74) [26]. It is clear that a 
risk calculation in the first trimester would be the most effective method to prevent 
preeclampsia.
Since the data on the usefulness of early administration of aspirin is still emerging, 
the optimal dose, which is probably 70–160 mg/d, is still under investigation. There is a 
known aspirin resistance in 33% of all women, which justifies the introduction of at least 
100 instead of 80 mg aspirin/d. The combination of aspirin and low-molecular-weight 
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heparin in secondary prevention seems to bring an additional benefit over aspirin alone 
[27], especially for an additional hereditary thrombophilia [28].
Early detection is based on three main points which are focused on and comple-
ment each other: a detailed medical history, the collection of biophysical parameters 
such as blood pressure, arterial stiffness, and Doppler examination of maternal 
blood vessels, and the determination of biochemical parameters, which can give 
clues to impaired placental function.
4. Maternal risk factors
The risk factors that are involved in the development of preeclampsia are 
also the symptoms of the metabolic syndrome and glucose metabolism disorders 
such as diabetes mellitus as well as insulin resistance and assisted reproductive 
techniques, increased body mass index (>35 kg/m2), and increased diastolic blood 
pressure > 80 mm Hg [29]. Further risk factors are positive preeclampsia of genetic 
background, multiple pregnancy, pregnancy above the age of 40, previous kidney-
related problem, and coagulation problems [30, 31].
Specifically, prevalent coagulation problems connected with high risk of 
preeclampsia is factor V Leiden mutation, homozygous MTHFR mutation, hyper-
homocysteinemia, existence of antiphospholipid antibodies, and the mixture of 
multiple thrombophilias [32].
Immune system cause-related problems can be ascribed to the high risk, for 
instance, in the first pregnancy. In contrast, multiparity with the same partner has 
lower risk [33].
As to record, 30% of women with preeclampsia are identified early with inaccu-
rate positive rate of 5% [29]. As to the pregnancy-generated hypertension without 
preeclampsia, the motherly record is much more important than the maternal 
serum parameters and pulsatility indices of uterine arteries [34].
5. Parameters in biophysics
Mean pressure of arterial blood in the first trimester can be implemented in pairs 
with risk factors of maternity as a predictor of preeclampsia in the first trimester 
that has a detection rate of 76% for early-onset preeclampsia. Systolic blood pres-
sure is already substantially different in the first trimester regarding the early- and 
late-onset preeclampsia and pregnancy-generated hypertension [35].
The arterial supply to the uterus happens normally via uterine arteries, which 
change into circular running arteria arcuata. In this condition, the radial artery 
branches and spiral arteries move deeply into the myometrium and supply the 
decidua and fetus during pregnancy.
Anomalous placentation and incomplete cytotrophoblast invasion typified by 
inadequate formation and vasodilation of the spiral arteries have long been identi-
fied as one of the main risk factors for the growth of preeclampsia [36, 37].
These morphological changes indicate abnormal uteroplacental circulation typi-
cally characterized by a persistence of the postsystolic (Notch) and high resistance 
indices. A prediction of the severe form of pregnancy-induced hypertension and 
preeclampsia is possible by examining the uteroplacental vessels in the first and 
second trimesters. Various publications showed that in the first-trimester screen-
ing, Doppler examination of the uterine arteries identified a certain percentage of 
pregnant women that later develop preeclampsia with elevated uterine resistance 
indices and postsystolic incisions [38–40].
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About 40% of pregnant women can thus be detected at a false-positive rate 
of 5% [34, 41]. However, the sensitivity for the prediction of preeclampsia is 
significantly lower than that in the second-trimester ultrasound measurements. 
Higher rates of sensitivity regarding the discovery of a late-onset preeclampsia can 
be achieved in the second trimester of pregnancy. Several Doppler studies in the 
second trimester yielded detection rates of 70–80% [42, 43].
6. Biochemical parameters
The problem of the Doppler examination alone, however, lies in the low pre-
dictive value. Only in combination with biochemical markers, this evaluation is 
clinically relevant for a preventive therapy. In the second trimester, the combination 
of Doppler sonography and angiogenic factors such as PlGF/sEndoglin (sEng) and 
sFlt-1 is a valid prediction of preeclampsia [44].
In order to intervene preventively, high-risk population should be identified 
before the 16th week of pregnancy. The aim is, therefore, to predict preeclampsia at 
the first trimester of pregnancy.
PAPP-A was first identified as a predictive marker. PlGF is also in the first 
quarter of pregnancy decreased. Further promising targets for the first-trimester 
screening are PP-13, soluble endoglin, inhibin A, activin A, pentraxin 3, P-selectin, 
IGFBP-1 and IGFBP-3, adiponectin, resistin, l-arginine, asymmetric dimethylargi-
nine (ADMA), and homoarginine. However, sFlt-1 is not suitable for screening in 
the first trimester [34].
6.1 PIGF (placental growth factor)
PlGF belongs to the VEGF family, is secreted by trophoblast cells, and has 
proangiogenic function. Preeclampsia occurs due to an impaired placentation with 
subsequent ischemia triggers which raised secretion of antiangiogenic factors such 
as soluble Fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng) in the 
circulation of maternity. This process creates a course of antagonizing the angio-
genic factors such as PlGF [45].
PIGF was in an early focus of the research groups in the search for a suitable pre-
diction factor. It turned out that the concentration of PlGF in a preeclamptic preg-
nancy did not increase to the extent as would be expected in a normal pregnancy 
[46, 47]. Others could show that in the first trimester, there are already significant 
differences between PlGF concentrations in maternal blood of pregnant women 
with normal pregnancy and those that develop preeclampsia during pregnancy 
[34, 48–50]. Since 2011, the first conventional test of the company Alere allows the 
quantitative detection of PIGF in anticoagulated EDTA plasma in the first trimester 
with fluorescence immunoassay (sensitivity and specificity 95%). The detection 
rate of preeclampsia using PlGF alone for the early-onset preeclampsia is between 
41 and 59% and for late-onset preeclampsia 33% [51].
The latest studies show a strong connection between changed levels of PlGF 
and sVEGF R1 in preeclamptic pregnancy, as well as in those who will eventually 
develop the condition later in pregnancy. These reports are based on the find-
ings that sVEGF R1 levels increase earlier and to a greater extent in women who 
eventually develop preeclampsia compared to women with normal pregnancies. 
In contrast, free PlGF levels in women who develop preeclampsia (compared to 
women with normal pregnancies) are meaningfully lower. Latest data indicate these 
markers to be convincing in the differential examinations of hypertensive diseases 
of pregnancy [52, 53].
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6.2 sFlt-1/PlGF ratio
Researches show that sFlt-1 is an antiangiogenic molecule and therefore seems 
to be involved importantly in the pathogenesis of preeclampsia. High levels of 
circulatings sFlt-1 in early pregnancy are associated with the later commencement 
of preeclampsia. An in vitro research shows that sFlt-1 inhibits tube formation 
of endothelial cells from human umbilical vein. In essential cytotrophoblast cell 
culture, sFlt-1 production and mRNA expression are related inversely to oxygen 
saturation. A twofold elevation in the level of sFlt-1 was also observed when normal 
villous explants were exposed to a hypoxic state (1% oxygen), compared with physi-
ologic exposure to 5% oxygen. Therefore, it is reasonable that the hypoxic placenta 
releases an excess of sFlt-1 into the maternal circulation, which induces maternal 
endothelial dysfunction and clinical symptoms of preeclampsia. There is also a 
tendency that an excess of sFlt-1 production can trigger events in the pathogenesis 
of preeclampsia [55].
Especially, the sFlt-1/PlGF ratio connects to the clinical condition of the disease, 
differentiates between healthy and preeclamptic pregnancies, and gives a short-
term prediction of disease development. Consequently, the estimation of sFlt-1 and 
PlGF was measured in clinical routine as a reliable and meaningful tool in examin-
ing and monitoring PE [56].
Research on antiangiogenesis factors such as sFlt-1 failed to convince as the 
exclusive marker for the prediction of preeclampsia in the first trimester [51]. 
Verlohren et al. showed that the combination of angiogenesis and antiangiogenesis 
factors, at least in the second and third trimesters, may offer the possibility of a risk 
classification by an sFlt-1/PlGF ratio. It was found that patients with preeclampsia 
Figure 2. 
An excessive production of sFlt-1 is known in patients with preeclampsia. As an antagonist, it binds with high 
affinity to free PIGF in maternal serum. Thereby, proangiogenic effects by binding of PIGF to membranous 
sFlt-1 receptors (a vascular endothelial growth factor) are inhibited and are thought to be responsible for 
endothelial dysfunction.
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had a significantly increased sFlt-1/PlGF ratio compared to patients with a normal 
pregnancy [16, 57, 58] (Figure 2).
6.3 PAPP-A
Pregnancy-associated plasma protein A (PAPP-A), an insulin-like growth factor-
binding protein protease, is secreted by the syncytiotrophoblast. As part of the 
first-trimester screening, it has long been used in risk calculation for chromosomal 
abnormalities. We could show that patients with decreased levels of PAPP-A in 
maternal blood during the first trimester develop preeclampsia [54], especially an 
early-onset preeclampsia as revealed also by others [34, 59, 60, 74].
6.4 Inhibin A and activin A
Both glycoprotein hormones are produced by the fetoplacental unit. Several 
studies exhibited that both inhibin A and activin A are increased in the first tri-
mester in maternal blood of patients who later develop preeclampsia compared 
to pregnant women with normal pregnancies [60, 61]. However, no association is 
found between impaired trophoblast invasion and subsequent endothelial dysfunc-
tion and increased concentration of activin A [62].
6.5 PP13
The placental protein 13 plays a role in physiological placentation. Because of 
impaired placentation in the presence of preeclampsia, there is an increased secre-
tion of PP13 in the first trimester of pregnancy [63–67].
6.6 PTX3
Pentraxin 3 is a secreted protein as part of an inflammatory immune response 
and is increased as an acute phase protein molecule [62]. Both with manifestations 
of PE and before clinical symptoms, there is an increased secretion of PTX 3 in the 
maternal circulation [60, 68–70].
6.7 P-selectin
As a cell adhesion molecule, P-selectin plays a role in endothelial dysfunction. 
The consequence of placental ischemia in the context of preeclampsia is endothelial 
dysfunction and thus increased secretion of P-selectin [71]. This is already detect-
able in the first trimester of pregnancy [60, 69, 70].
6.8 IGFBP-1 and IGFBP-3
Both insulin-like growth factor-binding proteins are the focus of new research. 
Both in early- and late-onset preeclampsia, IGFBP-1 is decreased in the first trimes-
ter. Such changes are detected by secretion of IGFBP-3 only in late-onset pre-
eclampsia. In both cases, there is no correlation to a disturbed trophoblast invasion 
[72, 73].
6.9 Adiponectin
In the case of early-onset PE, adiponectin levels are higher than in the first 
trimester compared to normal controls. This does not apply to late-onset PE. There 
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is no relationship between adiponectin and PAPP-A levels and Doppler values. In 
addition, there is no advantage in prediction by the addition of adiponectin [75].
6.10 Resistin
Resistin levels in the first trimester are higher in patients who develop preeclamp-
sia than controls. There is no relationship to impaired placental perfusion [75].
6.11 l-Arginine, asymmetric dimethylarginine (ADMA), and homoarginine
All three substances are part of NO metabolism. l-Arginine and l-homoarginine 
are increased in the first trimester at later-developing early-onset preeclampsia, as 
well as the ratio of ADMA/l-arginine and ADMA/L-homoarginine. This is not the 
case for late-onset preeclampsia and for the isolated analysis of ADMA [76].
7. Outlook
All biophysical and biochemical markers shown are used for prediction of 
preeclampsia. Meanwhile it has been obvious that a single diagnostic marker is not 
strong enough to accurately assume subsequent preeclampsia. Based on this reason, 
seemingly it is convincing to use historical, biophysical, and several biochemical 
parameters to ascertain the best possible detection rate is achieved.
Finally, one must distinguish between early- and late-onset preeclampsia in order 
to classify the present results correctly. The early-onset preeclampsia is defined 
as the onset before 34 weeks of pregnancy, the intermediate-onset preeclampsia 
between the 34 and 37 weeks, and the late-onset preeclampsia after 37 weeks. The 
late-onset PE seems to follow a different pathogenetic mechanism, since the serum 
parameters differ significantly as a marker of disturbed placentation in terms of 
predictive power [34]. The placentation disorder, according to previous published 
data, is a feature of early preeclampsia. The addition of biochemical markers in the 
first trimester is therefore particularly suitable for detection of early preeclampsia.
Poon et al. pioneered the evaluation of a few serum parameters and maternal 
factors in order to achieve a good predictive power of early preeclampsia. The 
detection rate of early-onset PE is 93.1% in the first trimester by algorithms from 
maternal risk factors, mean arterial blood pressure, pulsatility index of the uterine 
arteries, PAPP-A, and PlGF. The detection rate for the late-onset PE with an appro-
priate algorithm is 44.9% [34].
These named parameters can now be purchased commercially and combined 
with appropriate software. Akolekar et al. found that the detection rate of pre-
eclampsia in the first trimester by a combination of several markers (PIGF, PAPP-A, 
PP13, inhibin A, activin A, sEndoglin, PTX3, P-selectin, blood pressure, Doppler 
sonography, and history) is increased significantly to a detection rate of 91% at a 
fixed 5% false-positive rate for early-onset PE, 79.4% for intermediate-onset PE 
(34–37th weeks of gestation), and 60% for late-onset PE [60]. The addition of these 
parameters allows a better predictive power of all forms of preeclampsia compared 
to the above-described relatively simple algorithm, having particular effect on a 
high detection rate for early-onset preeclampsia.
Further studies are expected that show which of the biochemical markers are 
really useful in clinical practice. The relation of costs and benefit must be explored.
Finally, the question arises that how far it may succeed in establishing the first-
trimester screening tests with the consecutive possible prevention by aspirin and/or 
low-molecular-weight heparin, as a screening in a large, unselected collective. Since 
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prevention is simple and inexpensive, the obstacle is much more on a personal and 
cost-intensive screening tool. The investigation regarding chromosome abnormalities 
will depend on the basis of the consequences of abnormal test results of many factors 
and is always carried out only in a preselected group. Examining on preeclampsia 
should be for a much larger group of pregnant women, not at least because of the 
higher risk to get preeclampsia as a chromosomal abnormal baby and the simplicity 
of prophylaxis. The other essential reason for early preeclampsia risk estimation is the 
fact that preeclamptic pregnant women have a bigger lifetime risk for suffering heart 
and blood vessel disease. Better observation of this collective of patients, changing of 
lifestyle factors, and health education could be an important step to reduce morbidity 
and mortality according to cardiovascular problems worldwide.
Currently, the aspect of fetal programming is in the main focus of research. 
Not only the mother also the offspring bears the consequences of preeclamptic 
pregnancy with mostly intrauterine growth restriction like elevated risk for cardio-
vascular diseases and behavioral disorders, for example.
It would be desirable in the future to integrate preeclampsia risk calculation to 
the regular prenatal care in the first trimester. Further studies on large collectives 
have to determine to what extent the false-positive and false-negative findings can 
lead in relation to health and economic disadvantages. Even an early screening 
should not replace careful pregnancy monitoring.
Finally, pregnancy is not only a short time in a woman’s life with the aim to 
deliver a baby but it is also an important time giving insights in women’s health 
status. As we already know, pregnancy may positively influence women’s health 
future as could be shown by studies which detected a reduced risk of developing 
breast cancer after pregnancy. As an indicator of risk factors, pregnancy is not only 
the beginning of taking care for a family but also for a better self-care [77].
8. Conclusion
To conclude, the best possible detection rate of preeclampsia seems to be convinc-
ing to apply historical, biophysical, and several biochemical parameters. A detailed 
medical history such as diabetes mellitus, assisted reproductive techniques, increase 
body mass index, family background, multiple pregnancy, pregnancy over 40 years, 
previous renal problem, and clotting disorder. The collection of biophysical param-
eters such as blood pressure, arterial stiffness, and Doppler examination of maternal 
blood vessels. The determination of biochemical parameter such as angiogenic 
factors PIGF, sFlt-1, PAPP-A, inhibin A, activin A, PP13, PTX3, P-selectin, IGFBP-1 
and IGFBP-3, adiponectin, resistin, l-arginine, ADMA, and homoarginine.
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